Healthcare Global Enterprises Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹732 Cr +13.1% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
HG

Healthcare Global Enterprises Ltd

Q3 FY26Healthcare Services

Healthcare Global Enterprises Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹633Cr
+13.3% YoY
−2.1% QoQ
Net profit
−₹8Cr
Q3 FY25: ₹8 Cr
Margin
17.31%
+1.5 pp YoY
−1.7 pp QoQ
Price₹726
Market cap₹10.7K Cr
P/E221.4

The short version

Expected sales growth is 15%+ annually, with aspirations to exceed this target. The company expects sales growth of 15%+, with about 10% coming from volume growth and 5% from ARPP growth (Page 16).

From Healthcare Global Enterprises Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Expected sales growth is 15%+ annually, with aspirations to exceed this target.
  • Growth drivers: approximately 10% from volume growth and about 5% from Average Revenue per Patient (ARPP) growth.
  • Existing facilities currently operate at ~60% revenue potential, indicating significant headroom for growth.
  • Incremental bed additions of around 1,000 beds planned over the next 3-4 years, boosting capacity from ~2,200 to ~3,200+ beds.
  • Volume growth of about 8%-10% expected in key markets like Vizag and Bangalore.
  • New facilities launching include North Bangalore (120+ beds) by end of FY '27 and Whitefield in Bangalore.

2 more points from Healthcare Global Enterprises Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Healthcare Global Enterprises Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Expected capex for current year (FY '26) is about INR 275 crore - INR 280 crore.
  • Capex for next year (FY '27) is expected to be 10% - 12% higher than FY '26.
  • Planned addition of about 1,000 beds over the next 3-4 years, increasing from around 2,500-2,600 beds to about 3,500 beds.
  • Two upcoming greenfield projects in Bangalore (North Bangalore with 120+ beds and Whitefield), expected operational by end of FY '27.
  • Addition of about 20 beds by reconfiguring specs of the existing Centre of Excellence in Bangalore.

2 more points from Healthcare Global Enterprises Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Healthcare Global Enterprises Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The focus of the discussion is primarily on financial performance, growth plans, bed capacity expansion, sales growth drivers (ARPP and volume), capex guidance, and operational metrics. There is no reference to order books or pending orders in the Q3 & 9M FY26 earnings call transcript or associated documents.

Healthcare Global Enterprises Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Healthcare Global Enterprises Ltd Q3 FY26 results — key figures

Healthcare Global Enterprises Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue633559+13.3%647-2.1%
Operating profit (EBITDA)11088+24%123-11.2%
Operating margin17.31%15.82%+1.5 pp19.06%-1.7 pp
Profit before tax-6-3—20-130.6%
Net profit (PAT)-88-201.9%21-138.2%
EPS (₹)-0.660.50-232%1.15-157.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹732 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q3 FY26)

    FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —

  • Aster DM Quality (Q3 FY26)

    Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…

  • Chandan Healthca (Q3 FY26)

    The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…

  • Rainbow Childrens Medicare (Q3 FY26)

    Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Healthcare Global Enterprises Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Healthcare Global Enterprises Ltd Q3 FY26 results?

Expected sales growth is 15%+ annually, with aspirations to exceed this target. The company expects sales growth of 15%+, with about 10% coming from volume growth and 5% from ARPP growth (Page 16).

What is Healthcare Global Enterprises Ltd share price analysis?

Healthcare Global Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 221.3 with a market cap of ₹10,665 Cr. Investors should review the full earnings analysis for detailed insights.

Is Healthcare Global Enterprises Ltd planning capital expenditure?

Expected capex for current year (FY '26) is about INR 275 crore - INR 280 crore.

Keep Healthcare Global Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.